Stay updated with breaking news from Christopherh Evans. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Proceeds will be used to advance clinical program of GNSC-001, company's lead candidate in osteoarthritis (OA) Brian Kotzin, M.D., and Jackson Streeter, M.D.,...
Share this article PALO ALTO, Calif., May 5, 2021 /PRNewswire/ -- Â Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA). GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involve...